Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma

• Yao Liang ,

  Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing

  * E-mail: liang.yao@med.nagoya-u.ac.jp

  Affiliation Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan

  https://orcid.org/0009-0005-2365-1513

  ⨯
• Osamu Maeda,

  Roles Investigation, Methodology, Supervision, Writing – review & editing

  Affiliation Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan

  ⨯
• Chiaki Kondo,

  Roles Conceptualization, Writing – review & editing

  Affiliation Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan

  ⨯
• Kazuki Nishida,

  Roles Formal analysis, Methodology, Validation, Writing – review & editing

  Affiliation Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Aichi, Japan

  ⨯
• Yuichi Ando

  Roles Conceptualization, Investigation, Methodology, Project administration, Resources, Supervision, Writing – review & editing

  Affiliation Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan

  https://orcid.org/0000-0002-6849-2297

  ⨯